MA34815B1 - Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer - Google Patents
Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancerInfo
- Publication number
- MA34815B1 MA34815B1 MA36091A MA36091A MA34815B1 MA 34815 B1 MA34815 B1 MA 34815B1 MA 36091 A MA36091 A MA 36091A MA 36091 A MA36091 A MA 36091A MA 34815 B1 MA34815 B1 MA 34815B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- cancer
- compositions
- treatment
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des procédés de traitement de patients avec cancer, dans lesquels les procédés comprennent l'administration au patient d'une quantité efficace d'un inhibiteur de MEK et d'une quantité efficace d'un inhibiteur de PI3K. Les compositions dans lesquelles les inhibiteurs de MEK et de PI3K sont combinés sont aussi décrites.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42146510P | 2010-12-09 | 2010-12-09 | |
US201161436258P | 2011-01-26 | 2011-01-26 | |
US201161467485P | 2011-03-25 | 2011-03-25 | |
FR1159940 | 2011-11-03 | ||
PCT/US2011/063871 WO2012078832A1 (fr) | 2010-12-09 | 2011-12-08 | Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34815B1 true MA34815B1 (fr) | 2014-01-02 |
Family
ID=45464841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36091A MA34815B1 (fr) | 2010-12-09 | 2011-12-08 | Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer |
Country Status (22)
Country | Link |
---|---|
US (1) | US20140024653A1 (fr) |
EP (1) | EP2648729A1 (fr) |
JP (1) | JP2013544892A (fr) |
KR (1) | KR20140011311A (fr) |
CN (1) | CN103402518A (fr) |
AR (1) | AR084216A1 (fr) |
AU (1) | AU2011338354A1 (fr) |
BR (1) | BR112013014198A2 (fr) |
CA (1) | CA2820748A1 (fr) |
CL (1) | CL2013001643A1 (fr) |
CR (1) | CR20130246A (fr) |
DO (1) | DOP2013000131A (fr) |
MA (1) | MA34815B1 (fr) |
MX (1) | MX2013006319A (fr) |
NZ (1) | NZ611581A (fr) |
PE (1) | PE20140702A1 (fr) |
RU (1) | RU2013131241A (fr) |
SG (1) | SG190368A1 (fr) |
TW (1) | TW201306837A (fr) |
UY (1) | UY33790A (fr) |
WO (1) | WO2012078832A1 (fr) |
ZA (1) | ZA201303687B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201491836A1 (ru) * | 2012-04-06 | 2015-02-27 | Санофи | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek |
KR102157501B1 (ko) * | 2012-10-11 | 2020-09-18 | 메르크 파텐트 게엠베하 | 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 mek 억제제와의 조합 |
JP2017505321A (ja) * | 2014-02-07 | 2017-02-16 | ベラステム・インコーポレーテッドVerastem,Inc. | 異常な細胞成長を処置するための方法および組成物 |
WO2016014390A1 (fr) * | 2014-07-25 | 2016-01-28 | Merck Patent Gmbh | Compositions et méthodes pour polythérapie à base d'inhibiteurs de mek dans le traitement du cancer |
TW201930880A (zh) * | 2017-12-22 | 2019-08-01 | 瑞士商艾迪安納股份有限公司 | 用於測定抗-cd26配體的生物學活性之定量的細胞法 |
WO2021047783A1 (fr) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer |
KR20230088451A (ko) * | 2020-10-16 | 2023-06-19 | 메모리얼 슬로안 케터링 캔서 센터 | 암 요법을 위한 페롭토시스의 유도 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
-
2011
- 2011-12-07 AR ARP110104595A patent/AR084216A1/es unknown
- 2011-12-08 JP JP2013543331A patent/JP2013544892A/ja not_active Abandoned
- 2011-12-08 RU RU2013131241/15A patent/RU2013131241A/ru not_active Application Discontinuation
- 2011-12-08 EP EP11806025.0A patent/EP2648729A1/fr not_active Withdrawn
- 2011-12-08 MA MA36091A patent/MA34815B1/fr unknown
- 2011-12-08 PE PE2013001394A patent/PE20140702A1/es not_active Application Discontinuation
- 2011-12-08 MX MX2013006319A patent/MX2013006319A/es not_active Application Discontinuation
- 2011-12-08 CN CN2011800671706A patent/CN103402518A/zh active Pending
- 2011-12-08 TW TW100145212A patent/TW201306837A/zh unknown
- 2011-12-08 SG SG2013039367A patent/SG190368A1/en unknown
- 2011-12-08 WO PCT/US2011/063871 patent/WO2012078832A1/fr active Application Filing
- 2011-12-08 KR KR1020137017879A patent/KR20140011311A/ko not_active Application Discontinuation
- 2011-12-08 CA CA2820748A patent/CA2820748A1/fr not_active Abandoned
- 2011-12-08 AU AU2011338354A patent/AU2011338354A1/en not_active Abandoned
- 2011-12-08 BR BR112013014198A patent/BR112013014198A2/pt not_active IP Right Cessation
- 2011-12-08 NZ NZ611581A patent/NZ611581A/en not_active IP Right Cessation
- 2011-12-09 UY UY0001033790A patent/UY33790A/es not_active Application Discontinuation
-
2013
- 2013-05-21 ZA ZA2013/03687A patent/ZA201303687B/en unknown
- 2013-05-27 CR CR20130246A patent/CR20130246A/es unknown
- 2013-06-07 CL CL2013001643A patent/CL2013001643A1/es unknown
- 2013-06-07 DO DO2013000131A patent/DOP2013000131A/es unknown
- 2013-06-07 US US13/912,647 patent/US20140024653A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG190368A1 (en) | 2013-06-28 |
CA2820748A1 (fr) | 2012-06-14 |
ZA201303687B (en) | 2014-01-29 |
KR20140011311A (ko) | 2014-01-28 |
BR112013014198A2 (pt) | 2016-09-13 |
RU2013131241A (ru) | 2015-01-20 |
PE20140702A1 (es) | 2014-06-26 |
UY33790A (es) | 2012-07-31 |
EP2648729A1 (fr) | 2013-10-16 |
NZ611581A (en) | 2015-02-27 |
JP2013544892A (ja) | 2013-12-19 |
CN103402518A (zh) | 2013-11-20 |
MX2013006319A (es) | 2013-07-03 |
DOP2013000131A (es) | 2013-11-15 |
WO2012078832A1 (fr) | 2012-06-14 |
AR084216A1 (es) | 2013-05-02 |
AU2011338354A1 (en) | 2013-06-27 |
US20140024653A1 (en) | 2014-01-23 |
TW201306837A (zh) | 2013-02-16 |
CR20130246A (es) | 2013-09-03 |
CL2013001643A1 (es) | 2014-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34815B1 (fr) | Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer | |
PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
IN2015DN00376A (fr) | ||
MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
TN2015000168A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
MX2021008610A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
EA201491008A1 (ru) | Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EA200971053A1 (ru) | Способы лечения кожных язв | |
BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
EP4124346A3 (fr) | Compositions et procédés de traitement de maladies | |
EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
TN2016000040A1 (fr) | Inhibiteurs de porc2 et procedes pour leur utilisation | |
EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
MX2014005749A (es) | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). | |
WO2008073466A3 (fr) | Alpha b-cristalline en tant que traitement de l'inflammation | |
TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
MX357770B (es) | Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer. | |
EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek | |
MA37930A1 (fr) | Procédés pour le traitement du cancer utilisant le lipoplatine |